Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of upadacitinib in ulcerative colitis
CTR20171683Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of upadacitinib in autoimmune colitis, sponsored by AbbVie Inc.. Started Apr 2020; status: active.
02
Drugs
upadacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20171683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171683.